⚠Companies House status: Dissolved · last active 12 Jun 2025 — this supplier should not receive new awards without further checks.

UL Global Pharma

SMEUK · LiverpoolCompany No. 08482877

UL Global Pharma is a UK limited company, based in Liverpool, incorporated in 2013. Has won 13 UK public-sector contracts worth £52.6m across 3 buyers, primarily NHS England.

⇄ Compare peers ⇩ Export ↗ Share

Active contracts

no new awards in 30d

Contracted (12m)

—

no data

Public buyers

stable this month

Top buyer share

100%

NHS England

Risk signals · 2 active

Derived from Companies House filings. More sources (HMRC, Insolvency Service register, press) will be added incrementally.

⚑

Company status: Dissolved

Companies House records this company as last active 12 Jun 2025. New awards should be paused pending resolution.

HIGH

⚑

Insolvency case on record (1)

Most recent: members voluntary liquidation appointed 25 Sept 2023.

HIGH

Buyer concentration

Each block sized by share of total award value. A dominant block signals dependency on one buyer.

Severe concentration. Top buyer alone = 100% of revenue.

NHS England

£52.6m

100%

Leeds Teaching Hospitals

—

The NHS Commissioning Board (operating under the name of NHS England)

—

Contracts won · 13 total · 8 active · 5 expired

Every contract award published under the Procurement Act.

Sort

Title	Buyer	Award type	Value	Awarded	Status
NHS Midland & East Branded Medicines, Tranche B & Annual Tranche	NHS England	Shared contract	£13.7m lot total · 35 suppliers	13 Feb 2023	expired
NHS Framework Agreement, Branded Medicines for London and South of England	NHS England	Framework call off	£13.3m ceiling · ~£317k share (÷42)	19 Aug 2021	expired
NHS Framework Agreement for South of England Branded - Tranche B and Annual	NHS England	Shared contract	£11.7m lot total · 29 suppliers	15 Jul 2022	expired
NHS Framework for the North of England, Branded Medicine	NHS England	Framework call off	£7.7m ceiling · ~£249k share (÷31)	07 Feb 2022	expired
NHS Framework for the Midlands and East, Branded Medicines - Tranche B	NHS England	Shared contract	£6.2m lot total · 37 suppliers	25 Jan 2021	expired
NHS Framework Agreement for Branded Medicines – National	NHS England	Direct contract	—	—	active
NHS Framework Agreement for Branded Medicines – National	NHS England	Direct contract	—	—	active
NHS Framework Agreement, Branded Medicines for London and South of England	NHS England	Direct contract	—	—	active
NHS Framework Agreement, Branded Medicines for London and South of England	NHS England	Direct contract	—	—	active
Framework Agreement for the supply of unlicensed imported medicines services and product	Leeds Teaching Hospitals	Direct contract	—	—	active
NHS Framework Agreement for South of England Branded - Tranche B and Annual	NHS England	Direct contract	—	—	active
NHS Framework for the North of England, Branded Medicine	The NHS Commissioning Board (operating under the name of NHS England)	Direct contract	—	—	active
NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.	The NHS Commissioning Board (operating under the name of NHS England)	Direct contract	—	—	active

UL Global Pharma

Risk signals · 2 active

Buyer concentration

Contracts won · 13 total · 8 active · 5 expired

Top buyers · by total award value

Category mix — CPV divisions

Geographic spread

Modifications received · scope growth on existing wins

Compliance scorecard

Financial health

Company information

Corporate structure

Companies House data

Peer suppliers

News mentions

Compliance scorecard

Financial health

Company information

Corporate structure

UL Global Pharma

Companies House data

Why Capita's public-sector share keeps slipping — and who's eating it

The 12 frameworks Capita bid on last year (and lost 8)

Is BPO concentration back? A supplier-risk deep-dive